Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO

Key Points

• Dimensional Fund Advisors increased its Lexeo Therapeutics position by 27.9% in the first quarter, adding 240,692 shares to hold 1.10 million shares worth approximately $6.3 million. Institutional investors collectively own 60.67% of LXEO.
• Lexeo insiders sold shares recently, including CEO Richard Nolan Townsend and insider Narinder Pal Bhalla, with the transactions reportedly made to cover tax withholding on vested equity awards. Insiders have sold 62,204 shares worth $280,089 over the past 90 days.
• LXEO opened at $4.78, near its 52-week low of $3.99, while analysts maintain a consensus “Buy” rating and an average price target of $18.75. The company’s latest quarterly loss of $0.25 per share beat the consensus estimate of a $0.29 loss.

Dimensional Fund Advisors LP increased its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 27.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,103,584 shares of the company's stock after purchasing an additional 240,692 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.41% of Lexeo Therapeutics worth $6,332,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of LXEO. Bleakley Financial Group LLC bought a new stake in Lexeo Therapeutics during the 1st quarter valued at $275,000. Avoro Capital Advisors LLC bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth $32,769,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth $37,000. Invesco Ltd. purchased a new position in shares of Lexeo Therapeutics during the fourth quarter valued at $4,598,000. Finally, Vestal Point Capital LP increased its stake in shares of Lexeo Therapeutics by 37.7% during the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company's stock valued at $44,437,000 after buying an additional 1,225,000 shares during the period. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 25,947 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the sale, the chief executive officer directly owned 377,817 shares in the company, valued at approximately $1,692,620.16. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the transaction, the insider directly owned 82,194 shares of the company's stock, valued at $363,297.48. The trade was a 21.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 62,204 shares of company stock worth $280,089 over the last ninety days. 2.00% of the stock is currently owned by corporate insiders.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $4.78 on Wednesday. The company's 50-day simple moving average is $4.63 and its 200-day simple moving average is $5.67. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $10.99. The stock has a market capitalization of $375.34 million, a P/E ratio of -3.30 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. On average, research analysts forecast that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current year.

Wall Street Analysts Forecast Growth

LXEO has been the subject of a number of research reports. Weiss Ratings lowered shares of Lexeo Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, July 30th. Chardan Capital raised shares of Lexeo Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating for the company in a research report on Thursday, June 25th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

Want to see what other hedge funds are holding LXEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source